European approval for Amicus' Galafold for Fabry disease

1 June 2016

US biotech Amicus Therapeutics (Nasdaq: FOLD) has received approval from the European Commission for Galafold (migalastat) as a treatment for patients diagnosed with Fabry disease and who have an amenable mutation.

Amicus started supplying the market in Germany on Monday and will begin the reimbursement processes with healthcare authorities in each of the major European countries.

The oral small molecule pharmacological chaperone Galafold is the first precision medicine approved for the disease. The broad label includes 269 Fabry-causing mutations which represent 35% to 50% of all patients with the disorder.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK